CTOR

Citius OncologyF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

Materiality

earnings

Source

External coverage

Decided

2026-08-18

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Negative earnings read-through for Citius Oncology after Q3 revenue missed forecasts despite LYMPHIR launch momentum.

View event details

Sentiment decomposition

30-day score

Company-55%

Macro-30%

Pulse-15%

Weekly research-10-day

Company, Macro, and Pulse form the existing 30-day artifact blend. Weekly research is tracked separately for 10 days and can contribute at most 10% of the sentiment pillar when live mode is enabled.

Recent headlines

Headline

Time

Relevance

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

2026-08-14

13%

External coverage

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

2026-08-14

13%

External coverage

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

2026-05-15

13%

External coverage

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

2026-05-15

13%

External coverage

Citius Oncology Ships First International Order of LYMPHIR to Europe

2026-04-29

13%

External coverage

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development

2026-03-31

External coverage

Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

2026-03-10

13%

External coverage

As of 2026-08-18 • Updated scheduledSource: News desk